First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1.
Neeta SomaiahMatthew S BlockJoseph W KimGeoffrey I ShapiroKhanh T DoPatrick HwuJoseph P EderRobin L JonesHailing LuJan H Ter MeulenChet BohacMichael ChenFrank J HsuSacha GnjaticSeth M PollackPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
This first-in-class, first-in-human study of LV305 demonstrated a favorable safety profile, induction of antigen-specific responses, and potential clinical activity in patients with advanced cancer.